Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cost-Consciousness Raising: Adding Value To Cancer Drug Development

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

As the market attempts to reconcile the high prices of revolutionary new cancer therapies with pressure to control rising health care costs, oncology associations call for new drugs to demonstrate clinical value in addition to meeting FDA’s standards of safety and efficacy. Can “continuous learning systems” help?


Related Content

ASCO “Top 5” List Turns Up Rhetorical Heat On Cancer Drug Prices
ASCO Linking E-Health Data To Promote Real-Time Personalized Cancer Care
Cancer Pathways Will Help Inform Drug Performance Measures, Payers Say


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts